2Aletaha D, Neogi T, Silman A J, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collab- orative initiative[J]. Arthritis Rheum, 2010, 62(9): 2569.
3Smolen J S, Aletaha D, Bijlsma J W J, et al. Treating rheumatoid arthritis to target: recommendations of an inter national task force[J]. Ann Rheum Dis, 2010, 69(4) : 631.
4Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBI- TION study[J]. Ann Rheum Dis, 2010, 69(01): 88.
5Fleisehmann R, Kremer J, Cush J, et al. Placebo con- trolled trial of tofacitinib monotherapy in rheumatoid arthritis [J]. N EnglJ Med, 2012, 367(6): 495.
6Sellam J, Hendel Chavez H, Roumlet S, et al. B ceil activa- tion biomarkers as predictive factors for the response to ritux- imab in rheumatoid arthritis: A six month, national, multi- center, open label study[J]. Arthritis Rheum, 2011, 63 (4): 933.
7Kremer J M, Blanco R, Brzosko M, et al. Tocilizumab in- hibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double blind treatment phase of a randomized placebo con- trolled trial of tocilizumab safety and prevention of structural joint danmge at one year[J]. Arthritis Rheum, 2011, 63 (3) : 609.
8Moreland L W, O'Dell J R, Paulus H E, et al. A random- ized comparative effectiveness study of oral triple therapy ver sus etanercept plus methotrexate in early aggressive rheuma toid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial[J]. Arthritis Rheum, 2012, 64(9): 2824.
